MLH1-deficient HCT116 colon tumor cells exhibit resistance to the cytostatic and cytotoxic effect of the poly(A) polymerase inhibitor cordycepin (3'-deoxyadenosine) in vitro

Imesch,Patrick; Goerens,Anouk; Fink,Daniel; Fedier,André

doi:10.3892/ol.2011.504

MLH1-deficient HCT116 colon tumor cells exhibit resistance to the cytostatic and cytotoxic effect of the poly(A) polymerase inhibitor cordycepin (3'-deoxyadenosine) in vitro

Authors:
- Patrick Imesch
- Anouk Goerens
- Daniel Fink
- André Fedier
View Affiliations

Affiliations: Department of Gynecology, University Hospital Zurich, CH-8091 Zurich, Switzerland
Published online on: December 1, 2011 https://doi.org/10.3892/ol.2011.504
Pages: 441-444

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cordycepin (3'-deoxyadenosine) is an inhibitor of poly(A) polymerase (PAP), an enzyme crucial to mRNA 3'-end processing, which produces the shortening of poly(A) tails, leading to the destabilization of mRNAs. Cordycepin inhibits proliferation and induces apoptosis in tumor cells, indicating its antitumor activity. Defective 3'-end processing is associated with hypersensitivity to UV treatment. We investigated the effects of cordycepin on proliferation and apoptosis in MLH1‑deficient and MLH1-proficient HCT116 colon tumor cells. MLH1 is a DNA mismatch repair (MMR) protein involved in the processing of damaged DNA. Cells with defective MMR show resistance to certain anticancer drugs. The results showed that MLH1-deficient HCT116 cells are 2-fold less sensitive to the cytostatic effect of cordycepin, as compared to MLH1-proficient cells. This reduced sensitivity to cordycepin in MLH1-deficient cells was associated with reduced upregulation of the cell cycle inhibitor p21. MLH1-deficient cells also exhibited reduced susceptibility to apoptosis upon treatment with cordycepin, as demonstrated by the reduced PARP-1 cleavage. Our findings showed that MLH1-deficient HCT116 colon tumor cells are resistant to the cytostatic and cytotoxic effect of cordycepin, indicating a possible involvement of MMR in mRNA polyadenylation. The findings also suggest that cordycepin is not suitable to therapeutically encounter tumor cells lacking MLH1 expression.

View Figures

View References

1	Penman S, Rosbash M and Penman M: Messenger and heterogeneous nuclear RNA in HeLa cells: differential inhibition by cordycepin. Proc Natl Acad Sci USA. 67:1878–1885. 1970. View Article : Google Scholar : PubMed/NCBI
2	Müller WE, Seibert G, Beyer R, Breter HJ, Maidhof A and Zahn RK: Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems. Cancer Res. 37:3824–3833. 1977.PubMed/NCBI
3	Wong YY, Moon A, Duffin R, Barthet-Barateig A, Meijer HA, Clemens MJ and de Moor CH: Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem. 285:2610–2621. 2010. View Article : Google Scholar : PubMed/NCBI
4	Chang W, Lim S, Song H, Song BW, Kim HJ, Cha MJ, Sung JM, Kim TW and Hwang K: Cordycepin inhibits vascular smooth muscle cell proliferation. Eur J Pharmacol. 597:64–69. 2008. View Article : Google Scholar : PubMed/NCBI
5	Chen LS, Du-Cuny L, Vethantham V, Hawke DH, Manley JL, Zhang S and Gandhi V: Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues. Biochem Pharmacol. 79:669–677. 2010. View Article : Google Scholar : PubMed/NCBI
6	Nakamura K, Konoha K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K and Kunitomo M: Effect of cordycepin (3′-deoxyadenosine) on hematogenic lung metastatic model mice. In vivo. 19:137–141. 2005.
7	Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K and Kunitomo M: Antitumor effect of cordycepin (3′-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation. Anticancer Res. 26:43–47. 2006.
8	Wu WC, Hsiao JR, Lian YY, Lin CY and Huang BM: The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line. Cancer Chemother Pharmacol. 60:103–111. 2007. View Article : Google Scholar : PubMed/NCBI
9	Chen LS, Stellrecht CM and Gandhi V: RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol. 140:682–691. 2008. View Article : Google Scholar : PubMed/NCBI
10	Scorilas A, Talieri M, Ardavanis A, Courtis N, Dimitriadis E, Yotis J, Tsiapalis CM and Trangas T: Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: a new independent prognostic marker in primary breast cancer. Cancer Res. 60:5427–5433. 2000.
11	Nazeer FI, Devany E, Mohammed S, Fonseca D, Akukwe B, Taveras C and Kleiman FE: p53 inhibits mRNA 3′ processing through its interaction with the CstF/BARD1 complex. Oncogene. 30:3073–3083. 2011.
12	Cevher MA, Zhang X, Fernandez S, Kim S, Baquero J, Nilsson P, Lee S, Virtanen A and Kleiman FE: Nuclear deadenylation/polyadenylation factors regulate 3′ processing in response to DNA damage. EMBO J. 29:1674–1687. 2010.PubMed/NCBI
13	Mirkin N, Fonseca D, Mohammed S, Cevher MA, Manley JL and Kleiman FE: The 3′ processing factor CstF functions in the DNA repair response. Nucleic Acids Res. 36:1792–1804. 2008.
14	Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 7:335–346. 2006. View Article : Google Scholar : PubMed/NCBI
15	Peltomäki P: Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 21:1174–1179. 2003.PubMed/NCBI
16	Fedier A and Fink D: Mutations in DNA mismatch repair genes: Implications for DNA damage signaling and drug sensitivity. Int J Oncol. 24:1039–1047. 2004.PubMed/NCBI
17	Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65:3980–3985. 2005. View Article : Google Scholar : PubMed/NCBI
18	Lee SJ, Moon GS, Jung KH, Kim WJ and Moon SK: c-Jun N-terminal kinase 1 is required for cordycepin-mediated induction of G2/M cell-cycle arrest via p21WAF1 expression in human colon cancer cells. Food Chem Toxicol. 48:277–283. 2010. View Article : Google Scholar : PubMed/NCBI
19	Danial NN and Korsmeyer SJ: Cell death: critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
20	Riedl SJ and Salvesen GS: The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 8:405–413. 2007. View Article : Google Scholar : PubMed/NCBI
21	Jeong JW, Jin CY, Park C, Hong SH, Kim GY, Jeong YK, Lee JD, Yoo YH and Choi YH: Induction of apoptosis by cordycepin via reactive oxygen species generation in human leukemia cells. Toxicol In Vitro. 25:817–824. 2011. View Article : Google Scholar : PubMed/NCBI
22	Thomadaki H, Scorilas A, Tsiapalis CM and Havredaki M: The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer Chemother Pharmacol. 61:251–265. 2008. View Article : Google Scholar : PubMed/NCBI
23	Lui JC, Wong JW, Suen YK, Kwok TT, Fung KP and Kong SK: Cordycepin induced eryptosis in mouse erythrocytes through a Ca²⁺-dependent pathway without caspase-3 activation. Arch Toxicol. 81:859–865. 2007. View Article : Google Scholar : PubMed/NCBI
24	Nehmé A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY and Christen RD: Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer. 79:1104–1110. 1999.PubMed/NCBI
25	Wu Q and Vasquez KM: Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair. PLoS Genet. 4:1–10. 2008.PubMed/NCBI
26	Yoshioka K, Yoshioka Y and Hsieh P: ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell. 22:501–510. 2006. View Article : Google Scholar : PubMed/NCBI